List view / Grid view

Prof. Klaus Dugi

Filter the results

 

Prof. Klaus Dugi serves as Corporate Senior Vice President of Medicine and Chief Medical Officer at Boehringer Ingelheim GmbH.

news

Boehringer Ingelheim receives two FDA approvals

Boehringer Ingelheim today announced the U.S. Food and Drug Administration…

4 August 2014 | By Boehringer Ingelheim

Boehringer Ingelheim today announced the U.S. Food and Drug Administration (FDA) approved two different products at the end of last week.

news

New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin in adults newly diagnosed with Type 2 Diabetes

Boehringer Ingelheim (BI) and Eli Lilly and Company today announced…

3 December 2013 | By Boehringer Ingelheim

Boehringer Ingelheim (BI) and Eli Lilly and Company today announced new data1 from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with metformin (1500 or 2000 mg) in treatment-naive adults with newly diagnosed (<12 months) uncontrolled Type 2 Diabetes (T2D).